Table D8. Participant baseline characteristics

| Author, YearTrial Name | Baseline Age - Mean (SD)  | Baseline % Female  | Race/Ethnicity %  | Other Baseline Characteristics Reported  | Specify Characteristic and Group Differences  | Add Comments or Specify "Other" Entries  |
| --- | --- | --- | --- | --- | --- | --- |
| Bender et al., 20101NA | Overall N: NRG1: 39.6 (12.8)G2: 43.5 (14.3) | Overall N: NRG1: 60%G2: 68% | **White**G1: 56%G2: 60% **Hispanic**G1: 24%G2: 12%**African American**G1: 20%G2: 20%**Asian**G1: 0%G2: 8% | No | NA | **Other (Theory)**: Benefit-risk model of health behavior. |
| Berg et al., 19972NA | Overall N: 55G1: 47 (15)G2: 52 (15) | Overall N: 55G1: 21 (68%)G2: 15 (62%) | Overall N: 55**Caucasian**G1: 29 (93%)G2: 23 (96%) **non-Caucasian**G1: 2 (7%)G2: 1 (4%) | Yes | **Income**Overall N: 55<10KG1: 20%G2: 12%10-30KG1: 43% G2: 29%30-50%G1: 17%G2: 25%**Insurance (yes)**G1: 93%G2: 87%**Health problems**G1: 48%G2: 54% |  |
| Berg et al., 19972NA(continued) |  |  |  |  | **Asthma severitymoderate**G1: 71%G2: 79%severeG1: 29% G2: 21%**Health Problems** (yes)G1: 48%G2: 54%**Chronolog compliance mean** (SD)G1: 43 (29)G2: 40 (26)No sig diff |  |
| Berger et al., 20053NA | Overall N: 367Overall age: 45.98 (9.13)G1: NRG2: NR | Overall N: 367Overall % female: 82.8G1: NRG2: NR | Overall N: NRG1: NRG2: NR | No | NR |   |
| Bogner et al., 20084NA | Overall N: 64G1: 59.7 (7.3)G2: 57.5 (6.3) | Overall N: G1: 24 (75.0)G2: 25 (78.1) | African American, n (%)G1: 25 (78.1) G2: 28 (87.5) | Yes | **SF-36 scores:****Physical function score, mean (SD)** G1: 54.1 (33.2)G2: 64.5 (34.9)p= .22**Social function score, mean (SD)** G1: 75.6 (37.6) G2: 83.8 (33.5) p=.37 | **Funding** multiple sources: American Heart Association Grant-in-Aid, and an NIMH Mentored Patient-Oriented Research Career Development Award **Theory**: Integrated Care Model |
| Bogner et al., 20084NA(continued) |  |  |  |  | **Role physical score, mean (SD)**G1: 55.5 (42.0)G2: 65.6 (42.5) p= .34**Role emotional score, mean (SD)**G1: 63.5 (46.7)G2: 74.0 (43.0)p= .36**Bodily pain score, mean (SD)**G1: 46.3 (33.1)G2: 60.6 (35.7) p= .10**Other covariates****MMSE, mean (SD)**G1: 27.7 (2.7)G2: 27.9 (3.2) p= .73**Number of medications, N (SD)**G1: 8.6 (5.1)G2: 7.0 (3.6) p= .16**Outcome measures****CES-D, mean (SD)** G1: 17.5 (13.2)G2: 19.6 (14.2)p=.54 |  |
| Bogner et al., 20084NA(continued) |  |  |  |  | **Systolic BP, mean (SD), mm Hg** G1: 146.7 (20.9)G2: 143.1 (22.5) p= .51**Diastolic BP, mean (SD), mm Hg**G1: 83.0 (10.7) G2: 81.4 (11.1)p=.58≥**80% adherent to antidepressant, N (%)** G1: 14 (43.0)G2: 16 (50.0) p= .81**≥80% adherent to antihypertensive, N (%)**G1: 16 (50.0)G2: 11 (34.4) p= .31 |  |
| Bogner et al., 20105NA | Overall N: Mean (SD) = 60.2 (7.4)G1: 61.6 (8.3)G2: 58.3 (6.3) | Overall N: 84.5%G1: 82.8%G2: 86.2% | **Black**Overall N: 100%G1: 100%G2: 100% | Yes | **Less than high school education**Overall N: 13G1: 8 (27.6%)G2: 5 (17.2%)**Lives alone**Overall N: 27G1: 16 (55.2%)G2: 11 (37.9%) **Role Physical Score**Overall N: NRG1: 44.0 (39.9)G2: 64.5 (42.5) **Number of Medications** Overall N: NRG1: 10.2 (3.3)G2: 7.7 (3.2) **Adherent at baseline oral hypoglycemics** Overall N: NRG1: 34.5%G2: 20.7% **Adherent at baseline anti-depressants**Overall N: NRG1: 27.6%G2: 13.8% | **Funding source** Non-profit (American Diabetes Association) and Academic (University of Pennsylvania's Institute on Aging)**Theoretical model** Conceptual framework adapted from Cooper et al (source 33) |
| Bosworth et al., 20056V-STITCH | Overall N: NRG1: 63 (11.24)G2: 64 (11.48) | Overall N: NRG1: 2%G2: 2% | **White**Overall N: NRG1: 56G2: 58**African-American**Overall N: NRG1: 41G2: 39 | Yes | **High school or less, %**Overall N: NRG1: 50G2: 51**Inadequate income, %**Overall N: NRG1: 23G2: 21**Diabetic, %**Overall N: NRG1: 38G2: 42**Adherent to medications (based on self-report), %**Overall N: 66G1: NRG2: NR | **Additional theoretical model**: Health Decision **Theoretical Model** HDM |
| Bosworth et al., 20087TCYBBosworth et al., 20078TCYB Methods paper | Overall N: NRG1: 61 (12.7)G2: 62 (11.9) | Overall N: NRG1: 65G2: 67 | **Caucasian, %**Overall N: NRG1: 50%G2: 47%**African American, %**Overall N: NRG1: 47%G2: 51% | Yes | **12th grade or less** Overall N: NRG1: 35%G2: 38%**Functionally illiterate (REALM<=60), %**Overall N: NRG1: 27%G2: 27%**Inadequate income, %**Overall N: NRG1: 18%G2: 21%**Diabetic, %**Overall N: NRG1: 34%G2: 38% | **Funding source:** NHLBI, Pfizer Health Literacy Communication Initiative grant, American Heart Association Established-Investigator award**Theoretical model:** also Health Decision Model and motivational interviewing |
| Capoccia et al., 20049NA | Overall N: 74G1: 38.2 ± 13.8G2: 39.4 ± 13.4p=0.71 | Overall N: 57 (77)G1: 34 (83)G2: 23 (70)p=0.18 | **Non-White**Overall N: 16 (22)G1: 9 (22)G2: 7 (21)p=0.94 | Yes | **Annual householdincome <$30,000**Overall N: 19 (26)G1: 12 (29)G2: 7 (21)p=0.36**Panic disorder**G1: 9 (22)G2: 5 (15)p= 0.43**Neuroticism score** (Mean ± S.D. NEO)G1: 12.4 ± 6.1G2: 11.0 ± 5.5p= 0.31**Dysthymic disorder**G1: 23 (56)G2: 16 (48)p= 0.40**Prior antidepressant for depression**G1: 20 (49)G2: 12 (36)p= 0.28**Prior counseling or psychotherapy**G1: 17 (41)G2: 17 (52)p= 0.39 |  |
| Capoccia et al., 20049NA(continued) |  |  |  |  | **Mean ± S.D. SCL-20 score****No. (%) with SCID major depression**G1: 21 (53)G2: 9 (28)p= 0.04**Mean ± S.D. SF-12 Index (physical) score**G1: 49.6 ± 1.6G2: 52.6 ± 1.6p= 0.68**Mean ± S.D. SF-12 Index (mental) score**G1: 28.0 ± 1.6G2: 29.0 ± 1.7p= 0.20 |  |
| Carter et al., 200910NA | Overall N: NRG1: 57.3 (14.3)G2: 59.2 (13.8) | Overall N: NRG1: 62.5%G2: 55.7% | **White/Caucasian**Overall N: NRG1: 85.9%G2: 77.6%**African-American**Overall N: NRG1: 6.8%G2: 19.5%**American Indian**Overall N: NRG1: 0.5%G2: 1.0%**>1 Race or Other**Overall N: NRG1: 2.6%G2: 1.9% | Yes | **Low self-reported medication** **adherence (i.e., score >3) (%)**Overall N: NRG1: 8.9%G2: 9.1%NS**Household income <$25,000 (%)**Overall N: NRG1: 21.4%G2: 51.9%p < 0.001 |   |
| Carter et al., 200910NA(continued |  |  |  |  | **Insurance status (%):**Individual/group plan G1: 56.3%G2: 32.4%Medicare/MedicaidG1: 37.0%G2: 40.5%Self-pay or otherG1: 6.8%G2: 27.1%p < 0.001**Married**Overall N: NRG1: 67.7%%G2: 43.3%p: <0.001**BMI (kg/m^2) (Mean (SD))**Overall N: NRG1: 32.1 (6.8)G2: 34.2 (8.7)p: 0.010**Diabetes mellitus (%)**Overall N: NRG1: 19.8%G2: 38.1%p < 0.001**Heart failure (%)**Overall N: NRG1: 0.5%G2: 1.9%NS |  |
| Carter et al., 200910NA(continued |  |  |  |  | **Chronic kidney** **disease (%)**Overall N: NRG1: 5.7%G2: 7.6%NS**Angina (%)**Overall N: NRG1: 0.5%G2: 5.7%p < 0.003**Peripheral arterial disease (%)**Overall N: NRG1: 2.1%G2: 1.9%NS**Left ventricular hypertrophy (%)**Overall N: NRG1: 1.6%G2: 1.4%NS**>1 Coexisting condition (%)**Overall N: NRG1: 90.1%G2: 95.2%p=0.051**No. of coexisting conditions (Mean (SD))**Overall N: NRG1: 2.8 (1.8)G2: 3.6 (2.2)p < 0.001 |  |
| Chernew et al., 200811NA | Overall N (2004): G1: 37.4G2: 43.9Overall N (2005):G1: 38.0G2: 44.7 | Overall N (2004): G1: 53.5G2: 51.2Overall N (2005):G1: 53.5G2: 51.2 | NR | No | NA | "**Other" Theoretical Model** = None specified**"Other" Level of Randomization** = Not applicable |
| Choudhry et al., 201012NA | Total sample Overall N: NRG1: 58.8 (NR)G2: 67.5 (NR)G3: 53.8 (NR)G4: 54.5 (NR)G1 and G3: p<0.05G2 and G4 p<0.05 | Total sample Overall N: NRG1:36.1%G2: 37.6%G3: 39.8%G4: 28.8%G1 and G3: p<0.05G2 and G4 p<0.05 | **Black**Total sampleOverall N: NRG1: 11.5%G2:10.2%G3: 11.9%G4: *12.3%**G2 and G4 p<0.05* | Yes | **Income (Mean):**Overall: NRG1: $56,625G2: $54,715G3: $58,263G4: $57,286**Coronary artery disease (%):**Overall N: NRG1: 26.3%G2: 60.6%G3: 25.3%G4:43.8%**Congestive heart failure:**Total sample: Data NR**Statin users**Overall N: NRG1: 1.8%G2: 1.8%G3: 1.8%G4: 2.4%**Hypertension:**Overall: NRG1: 50.0%G2: 55.5%G3: 59.5%G4: 46.4% | Study design - Other = Interrupted time series with concurrent control groupLevel of randomization - Other = NATheoretical model - Other = Value-based insurance design strategy |
| Choudhry et al., 201012NA(continued) |  |  |  |  | **Diabetes**:Overall: NRG1: 36.2%G2: 12.6%G3 34.5%G4: 9.9%**Charlson comorbidity score:**Overall: NRG1: 1.0G2: 3.3G3: 1.0G4: 3.3**Monthly drug copay (year before copay reduction):**Overall: NRG1: $24.18G2: $17.22G3: $11.80G4: 10.65G1 and G3 differ on income, hypertension and copay at p < 0.05G2 and G4 differ income, CAD, Hypertension, diabetes and copay at p < 0.05 |  |
| Choudhry et al., 201113 | Overall N: 5855G1: 53.6 (7.6)G2: 53.7 (7.6) | Overall N: 5855G1: 24.4G2: 25.3 | Overall N: NRG1: NRG2: NR | Yes | **Congestive heart failure**Overall N: 5855G1: 27.0G2: 29.1**COPD**Overall N: 5855 G1: 15.7G2: 16.4**Diabetes**Overall N: 5855G1: 34.3G2: 34.8**Hypertension**Overall N: 5855G1: 71.2G2: 72.4**Previous MI**Overall N: 5855G1: 15.6G2: 17.4**Stroke**Overall N: 5855G1: 5.8G2: 6.7 | NA |
| Friedman et al., 199614NA | Overall N: 76G1: 76G2: 77 | Overall N: 77G1: 75G2: 79 | **Black %**Overall N: 11% G1: 10% G2: 11%  | Yes | **Education (%):**Overall N: NR1-11G1: 20G2: 3212G1: 55G2: 51 | **"Other" theoretical model** = none specified |
| Friedman et al., 199614NA(continued) |  |  |  |  | 13-17G1: 25G2: 17**Employed (%)**G1: 9G2: 10**Comorbid disease** (%)Heart diseaseG1: 29G2: 34StrokeG1: 6G2: 7DiabetesG1: 20G2: 16OtherG1: 80G2: 82**Mean number of comorbid disease**G1: 1.2G2: 1.2**Mean medication adherence**G1: 93G2: 94**Mean systolic BP (mm Hg)**G1: 169.5G2: 167 |  |
| Friedman et al., 199614NA(continued) |  |  |  |  | **Mean diastolic BP (mm Hg)**G1: 86.1G2: 84.0 |  |
| Fulmer et al., 199915NA | Overall N: 50G1: 73.1 (6.5)G2: 76.2 (8.8)G3: 73.7 (5.3) | Overall N: NRG1: G2:  | Overall N: 50**White**G1: 23.5G2: 20.0G3: 0.0**Black**G1: 23.5G2: 33.3G3: 33.3**Other**G1: 50.0G2: 46.7G3: 61.1 | yes | **Average compliance rates at BL**G1: 82%G2: 76%G3: 81% | **Funding Source:** Pharma, private foundation**Theoretical Model:** Article describes using a "stimulant strategy" |
| Grant et al., 200316NA | Overall N: (for all randomized to G1 and G2) NRG1: 63.3 (12.7)G2: 64.9 (12.1) Overall N: for completers (NR)G1: 64 (12)G2: 69 (10) | Overall (all randomized to G1 and G2) N: NRG1: 52G2: 51 Overall N (all completers): NRG1: 55G2: 69 | Overall N randomized: NR G1: % white: 79 G2: % white: 89 Overall N for completers: NRG1: % white: 87 G2: % white: 93  | Yes | **Baseline Medication Adherence (# days adherent in last 7 days)**Overall N for completers: NRG1: 6.7 (0.9) G2: 6.9 (0.4)**HbA1c (mean (SD))**Overall (all randomized to G1 or G2: NRG1: 7.7 (1.6)G2: 7.6 (1.4)Overall N (completers): NRG1: 7.7 (1.7)G2: 7.5 (1.1)**Number of Medicines (mean (SD))**Overall N (Completers): NRG1: 6 (2.8)G2: 5.8 (2.7) | **Other Theoretical Model** = None |
| Guthrie et al., 200117First Myocardial Infarction (MI) Risk Reduction Program | Overall N: 58.0 (NR)G1: 57.9 (NR)G2: 58.3 (NR) | Overall N: 51.1G1: 50.8G2: 52.4 | **White**Overall N: 79.9G1: 80.0G2: 79.6**Black**Overall N: 9.0G1: 9.0G2: 9.2**Hispanic**Overall N: 6.4G1: 6.4G2: 6.4**Asian**Overall N: 1.8G1: 1.7G2: 2.2 | Yes | **Prescription health plan, %**Overall N: 77.4G1: 77.5G2: 77.2**Level of education-elementary, %**Overall N: 9.8G1: 9.8G2: 9.4**Level of education-high school, %**Overall N: 53.8G1: 53.9G2: 53.4**Level of education-college, %**Overall N: 25.9G1: 25.8G2: 26.2**Level of education-graduate or professional, %**Overall N: 10.6G1: 10.5G2: 10.9 | **Theoretical model**: not specified**<$15,000, %**Overall N: 20.6G1: 21.0G2: 19.0**$15,001-$25,000, %**Overall N: 21.2G1: 21.2G2: 21.4**$25,001-$50,000, %**Overall N: 31.0G1: 31.1G2: 30.8**$50,001-$100,000, %**Overall N: 21.7G1: 21.1G2: 23.7**>$100,000, %**Overall N: 5.5G1: 5.6G2: 5.1**Diabetic (male), %**Overall N: 8.8G1: 8.1G2: 8.9**Diabetic (female), %**Overall N:9.8G1: 9.6G2: 9.8 |
| Hoffman et al., 200318NA | Overall N: NRG1: 51.9 (16.7)G2: 51.2 (16.5) | Overall N: 68G1: 67.9G2: 67.6 | NR | No | NA | **Other (Level of randomization):** random selection of zip codes of physicians' offices for inclusion in study. Allocation conducted by listing zip codes numerically and alternating arms.**Multiple funding sources:** Pharma companies & insurance provider**Theoretical Model:** No theoretical model reported |
| Hunt et al., 200819NA | Overall N: NRG1: 68 (12)G2: 68 (13) | Overall N: NRG1: 63G2: 66 | NR | Yes | **Comorbidities, N (%):**Overall N: NR**G1:** Asthma or COPD, 27 (12)Diabetes, 59 (26)History of stroke, 15 (7)Coronary artery disease, 46 (20)Renal impairment, 8 (3)One or more chronic conditions, 111 (48)Baseline systolic BP (mean (SD)), 173 (15)Baseline diastolic BP (mean (SD)), 90 (14) |   |
| Hunt et al., 200819NA(continued) |  |  |  |  | **G2**: Asthma or COPD, 27 (12)Diabetes, 57 (25)History of stroke, 6 (3)Coronary artery disease, 43 (18)Renal impairment, 6 (3)One or more chronic conditions, 103 (44)Baseline systolic BP (mean (SD)), 174 (15)Baseline diastolic BP (mean (SD)), 92 (14)**Education, college, N (%)**G1: 64 (28)G2: 65 (28) Only statistical sig between group difference was history of stroke, p=0.04 |  |
| Janson et al., 200320NA | Overall N: 65G1: 32 (9)G2: 35 (8) | Overall N: G1: 18 (55%)G2: 18 (56%) | NR | Yes | No group differences at baseline: **BL values: Adherence to inhaled corticosteroid (%)**G1: 70 (30) G2: 65 (34) | col X: no explicit theory used but testing whether imparting basic information and skills will lead to behavior that will improve asthma control |
| Janson et al., 200320NA(continued) |  |  |  |  | **Quality of life\***G1:27 (13)G2: 24 (14) **Perceived control of asthma**G1: 37 (6)G2: 42 (5) **Symptom severity**G1:11 (6)G2: 7 (6)**Beta-agonist (puffs)**G1: 4 (3) G2: 3 (3)**FEV1 (% predicted)**G1: 83 (17) G2: 80 (20)**Morning peak ﬂow (L/min)** G1: 446 (125) G2: 363 (97) **Eosinophil cationic protein**G1: 319 +/- 277 G2: 324 (346)**Tryptase ( g/L)**G1: 10 (22) G2: 3 (5)**Eosinophil’s (%)**G1: 6 (8)G2: 7 (12) |  |
| Janson et al., 200320NA(continued) |  |  |  |  | **Neutrophils (%)**G1: 39 (17) G2: 44 (19) |  |
| Janson et al., 200921NA | Overall N: 84G1: 36.8 +/- 9.4G2: 39.7 +/- 9.3 | Overall N: G1: 24 (53)G2: 21 (54) | **Asian**G1: 10 (22)G2: 6 (15)**Black**G1: 1 (2)G2: 4 (10)**White**G1: 28 (62)G2: 26 (67)**Other**G1: 6 (14)G2: 3 (8) | Yes | **Insured:** Overall N: G1: 37 (82) G2: 27 (69) **Severity by FEV1 criteria:** Severe (60% predicted value) G1: 22 (49) G2: 18 (46); **Adherence to ICS (%)**G1: 82 +/- 18G2: 81 +/- 18, p=.71only statistically sign difference across groups: peak flow**Peak ﬂow (morning only)** G1: 427.4 +/- 91.1G2: 381.8 +/- 110.2 , p=0.04**Other markers of severity**: Perceived asthma control score (11-55)G1: 41.8 +/- 6.1 G2: 40.2 +/- 4.2, p=.14 | **Funding sources** - gov't and pharma |
| Janson et al., 200921NA(continued) |  |  |  |  | **Asthma quality-of-life score (0-80)** G1: 16.0 +/- 11.0 G2: 15.8 +/- 11.1, p=.94**Peak ﬂow (morning only)**G1: 427.4 +/- 91.1 G2: 381.8 +/- 110.2, p=.04**Mean weekly puffs of b-agonist used** G1: 1.5 +/- 1.9G2: 1.7 +/- 2.2, p= .71**Mean weekly symptom score**G1: 4.5 +/- 4.4G2: 5.1 +/- 5.1, p=.55**Mean % symptom-free days per week** G1: 34.1 +/- 37.1G2: 31.0 +/- 37.2, p=.70**Mean weekly number of nighttime awakenings**G1: 0.29 +/- 0.69 G2: 0.35+/- 0.97, p=.75 |  |
| Johnson et al., 200622NR | Overall N: NRG1: NRG2: NR | Overall N: 49.6G1: NRG2: NR | **White**Overall N: 83.0G1: NRG2: NR**Black**Overall N: 5.8G1: NRG2: NR**Other**Overall N: 11.2G1: NRG2: NR | Yes | **Under $25,000, %**Overall N: 21.8G1: NRG2: NR**$25,000-$50,000, %**Overall N: 33.1G1: NRG2: NR**$50,000-$75,000, %**Overall N: 21.8G1: NRG2: NR**$75,000 or above, %**Overall N: 23.4G1: NRG2: NR |   |
| Johnson et al., 200623NR | Overall N: 55.7 (median) G1: NRG2: NR | Overall N: 47.0G1: NRG2: NR | **White**Overall N: 76.4G1: NRG2: NR**Black**Overall N: 16.1G1: NRG2: NR**Other**Overall N: 7.5G1: NRG2: NR | Yes | **Under $25,000, %**Overall N: 15.9G1: NRG2: NR**$25,000-$50,000, %**Overall N: 29.1G1: NRG2: NR**$50,000-$75,000, %**Overall N: 22.1G1: NRG2: NR**$75,000 or above,** **%**Overall N: 32.9G1: NRG2: NR | none |
| Katon et al., 199524NA | Overall N: 217Major depression group N=91G1: 43.2 (15.4)G2: 42.3 (12.7)Minor depression group N=126G1: 52.2 (14.3)G2: 50.3 (15.1) | Overall N: 217Major depression group N=91G1: 77.5G2: 88.1Minor depression group N=126G1: 76.3G2: 68.7 | NR | yes | Overall N: 217**SCL mean (SD) depression score**Major depression group N=91G1: 2.35 (0.49)G2: 2.23 (0.48)Minor depression group N=126G1: 1.67 (0.40)G2: 1.72 (0.56)**IDS mean (SD) score**Major depression group N=91G1: 46.6 (9.0)G2: 45.1 (11.2)Minor depression group N=126G1: 29.1 (9.6)G2: 28.0 (9.5)**Chronic disease score mean (SD) score**Major depression group N=91G1: 1.3 (1.9)G2: 0.6 (1.4)Minor depression group N=126G1: 2.3 (3.2)G2: 1.5 (1.9) | **Other Theoretical Model**: unspecified |
| Katon et al., 199625NA | Overall N: NRMajor Depression GroupG1: 43.1 (9.3)G2: 44.8 (15.9)Minor Depression GroupG1: 49.2 (13.9)G2: 47.2 (13.8) | Overall N: NRMajor Depression GroupG1: 77.4G2: 73.5Minor Depression GroupG1: 71.7G2: 73.8 | Overall N: NRMajor Depression Group (% White)G1: 77.4G2: 91.2Minor Depression Group (% White)G1: 91.3G2: 85.7 | Yes | **>1 year of college (%)**Major Depression GroupG1: 90.3G2: 70.6Minor Depression GroupG1: 87.0G2: 81.0**Chronic disease (mean (SD)):**Overall N: NRMajor Depression GroupG1: 1.19 (1.6)G2: 1.1 (2.0)Minor Depression GroupG1: 1.5 (2.6)G2: 1.2 (2.3)**Inventory of Depressive Symptoms Score (mean (SD))**Major Depression GroupG1: 46.8 (10.8)G2: 46.0 (8.8)Minor Depression GroupG1: 27.3 (7.4)G2: 28.2 (11.3) | Column X: "Other" Theoretical Model = Social Cognitive theory and Social Learning theory |
| Katon et al., 199625NA(continued) |  |  |  |  | **SCL-20 (mean (SD))**Major Depression GroupG1: 2.46 (0.53)G2: 2.35 (0.51)Minor Depression GroupG1: 1.77 (0.49)G2: 1.62 (0.54)**Recurrent major depression (>2 episodes)**Major Depression GroupG1: 59.1G2: 65.4Minor Depression GroupG1: 66.7G2: 64.9 |  |
| Katon et al., 200128 NALudman et al., 200329NAVan Korff et al., 200330NA | Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.)G1: 46.4 (11.9)G2: 45.6 (13.3) | Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.)G1: 75.4G2: 71.9 | Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.)**% Caucasian**:G1: 92.3G2: 88.0 | Yes | **Severity of Depression****% with major depression within past 2 years**Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.)G1: 78.5G2: 87.5p=0.01**SCL Depression Score (range 0 to 4), mean (SD)** G1: 0.83 (0.39) G2. 0.84 (0.35)**Comorbidity:Chronic Disease Score, mean (SD)**G1: 1051.4 (1228.0)G2: 1009.2 (994.5) | NA |
| Katon et al., 199926NAKaton et al., 200227NA | Overall N: NRG1: 47.2 (14)G2: 46.7 (13.4) | Overall N: NRG1: 67.5G2: 81.6p= 0.02  | **% Caucasian**Overall N: NRG1: 79.8G2: 80.7 | Yes | **Severity of Depression SCL Depression score**G1: 1.9 (0.5)G2: 1.9 (0.5)**Moderate depression:** N=149**Severe depression**: N=79**Recurrent depression (>= 3 episodes), %**G1: 76.3G2: 83.3**Dysthymia, %**G1: 40.0G2: 59.8**Chronic disease score; mean (SD)**G1: 1191.3 (978.5)G2: 1368.3 (1292.9) | **Other Randomization**;: Patients stratified by severity of disease (moderate or high) prior to randomization.**Other Theoretical Model**: NR |
| Lee et al., 200631FAME | \*Overall N: 78 (8.3)G1: 77 (10.5)G2: 78 (6.2) | \*Overall N: 22.9G1: 25.3G2: 26.3 | **White**Overall N: 63.7G1: 61.4G2: 56.5**Black**Overall N: 32.3G1: 34.9G2: 40.8 | Yes | **<High School, %**\*Overall N: 7.5G1: 3.7G2: 12.9**High School graduate, %**\*Overall N: 33.8G1: 32.1G2: 38.6**College graduate, %**\*Overall N: 21.4G1: 24.7G2: 18.6**Drug-treated hypertension, %**\*Overall N: 91.5G1: 92.8G2: 90.8**Drug-treated hyperlipidemia, %**\*Overall N: 80.6G1: 83.1G2: 80.3**BL adherence at completion of run-in phase, mean (SD)**Overall N: 61.2 (13.5)G1: 61.4 (13.0)G2: 61.1 (14.1) | **Other Theoretical Model =** not specified\*Overall N for baseline characteristics reported for beginning of run-in phase |
| Lin et al., 200632NA | Overall N: Mean (SD) = 58.5 (NR)G1: Mean (SD) = 58.6 (11.8)G2: Mean (SD) = 58.1 (12.0) | Overall N: 66.6%G1: 65.2%G2: 64.8% | **White**Overall N: 80%G1: 81.1%G2: 75.2%No other race/ethnicity data provided | Yes | **Type 2 Diabetes**Overall N: NRG1: 96.3%G2: 95.8%**Number of Diabetic Complications**G1: Mean (SD) = 1.5 (1.4)G2: Mean (SD) = 1.5 (1.3)**Major Depression (co-morbidity)**Overall N: NRG1: 62.6%%G2: 69.1%**>3 Previous Episodes of Depression (co-morbidity)**Overall N: NRG1: 68.6%G2: 60.5%**BL SCL-20 Score (Depression severity)**Overall N: NRG1: Mean (SD) = 1.7 (0.5)G2: Mean (SD) = 1.6 (0.5) | **Other Theoretical model** = Intervention design and procedures based on the Pathways Study (source 24) |
| Maciejewski et al., 201033NA | **Diuretics**Overall N: NRG1: 51.7 (7.9)G2: 52.0 (7.8)**ACE Inhibitors**Overall N: NRG1: 51.8 (8.0)G2: 52.2 (7.9)**Statins**Overall N: NRG1: 53.0 (7.3)G2: 53.4 (7.2)**Beta Blockers**Overall N: NRG1: 52.0 (8.2)G2: 52.4 (8.0)**Calcium Channel Blockers**Overall N: NRG1: 52.6 (7.8)G2: 52.8 (7.7)**Metformin**Overall N: NRG1: 51.6 (8.4)G2: 51.7 (8.3)**ARBS** Overall N: NRG1: 52.3 (7.6)G2: 52.6 (7.5) | **Diuretics**Overall N: NRG1: 55%G2: 63%**ACE Inhibitors**Overall N: NRG1: 38%G2: 45%**Statins**Overall N: NRG1: 38%G2: 46% **Beta Blockers**Overall N: NRG1: 46%G2: 54%**Calcium Channel Blockers**Overall N: NRG1: 40%G2: 48%**Metformin**Overall N: NRG1: 45%G2: 54%ARBS Overall N: NRG1: 45%G2: 54%  | Overall N: NRG1: NRG2: NR | Yes | Comorbidity burden (mean, SD)**Diuretics**Overall N: NRG1: 2.51 (2.59)G2: 2.51 (2.59)**ACE Inhibitors**Overall N: NRG1: 2.82 (3.01)G2: 2.85 (3.02)**Statins**Overall N: NRG1: 2.95 (3.03)G2: 2.95 (3.11)**Beta Blockers**Overall N: NRG1: 3.51 (3.53)G2: 3.59 (3.72)**Calcium Channel Blockers**Overall N: NRG1: 2.98 (3.24)G2: 3.09 (3.37)**Metformin**Overall N: NRG1: 2.87 (2.54)G2: 2.88 (2.60)**ARBS** Overall N: NRG1: 2.90 (3.01)G2: 2.91 (3.11) | NA |
| Maciejewski et al., 201033NA(continued) | **Cholesterol Absorption Inhibitors**Overall N: NRG1: 53.5 (7.1) G2: 53.8 (7.0) | **Cholesterol Absorption Inhibitors**Overall N: NRG1: 37%G2: 44% |  |  | **Cholesterol Absorption Inhibitors**Overall N: NRG1: 3.35 (3.19)G2: 3.40 (3.38) |  |
| Mann et al., 201034The Statin Choice | Overall N: 58 (11.5)G1: 58 (12)G2: 58 (11) | Overall N: Text states 58%, but the numbers in the table are not consistent with that G1: 74%G2: 75% | Overall N: Black or Latino: 89% G1: Black or Latino: NRG2: Black or Latino: NR | Yes | **< HS Education**Overall N: 44%G1: 51%G2: 36% **Mean HBA1c**Overall N: mean 7.5 (SD 2.0) G1: 7.0 (6.4, 8.7) (median (IQR)) G2: 6.7 (6.3, 7.6) (mean (IQR)) **10 year Cardiovascular Risk (%)**Overall N: < 15% risk: 53% 15-30% Risk: 44% > 30% Risk: 3%G1: < 15% risk: 53% 15-30% Risk: 40% > 30% Risk: 5%G2: < 15% risk: 54% 15-30% Risk: 41% > 30% Risk: 3% **BL Statin Use**Overall N: 69% G1: 69%G2: 69%  |  |
| Motori et al., 201135 | Overall N: NRG1: median 67 (range 51-84)G2: median 67 (range 50-82) | Overall N: 100G1: 100G2: 100 | Overall N: NRG1: NRG2: NR | Yes | **Annual income**Overall N: NRG1: Median 50000 (range 25000-90000)G2: Median 35000 (range 25000-70000) | NA |
| Murray et al., 200736NA | Overall N: NRG1: 61.4 (SD 7.7)G2: 62.6 (SD 8.8) | Overall N: NRG1: 68.0%G2: 66.1% | Overall N: NRG1: Black 45.1%, White 54.1%, Other 0.8%G2: Black 52.1%, White 46.9%, Other 1.0% | Yes | **Sufficient income**G1: 62%G2: 64%**Mean education**G1: 11 (SD 2)G2: 11 (SD 3)**Health literate**G1: 72%G2: 71%**Medicare**G1: 54.1%G2: 56.3%**Medicaid**G1: 30.3%G2: 36.5% |   |
| Nietert et al., 200937NA | Overall N: 60 (16)G1: 59.9 (16.7)G2: 60.6 (16.0)G3: 59.7 (16.5) | Overall N: NRG1: NRG2: NR | **Black**Overall N: NRG1: 16.3%G2: 16.3%G3: 16.5% | Yes | **Income (Mean (SD))**Overall N: NRG1: $33,573 ($9029)G2: $33751 ($9339)G3: $33471 ($9448)**Insurance Status**MedicaidG1: 16.4%G2: 13.2%G3: 15.7%OtherG1: 72.8%G2: 76.2%G3: 73.1%NoneG1: 10.8%G2: 10.6%G3: 11.2%**Disease indicationDiabetes**G1: 12.2%G2: 12.2%G3: 10.5%**Hypertension or heart failure**G1: 56.8%G2: 55.9%G3: 56.0%**Hyperlipidemia**G1: 17.2%G2: 16.9% G3: 17.7% | **Theoretical model - Other** = NS |
| Nietert et al., 200937NA(continued) |  |  |  |  | **Depression**G1: 13.2%G2: 14.6%G3: 15.1%**Psychosis**G1: 1.4%G2: 1.2%G3: 1.2% |  |
| Okeke et al., 200938NA | Overall N: NRG1: 66.2 (13.1)G2: 63.8 (13.4) | Overall N: NRG1: 48.6G2: 41.9 | **Black:**Overall N: NRG1: 65.7G2: 54.8**White**:Overall N: NRG1: 34.3G2: 41.9**Asian**:Overall N: NRG1: 0.00G2: 3.23 | Yes | **Family income based on zip code**:Overall N: NRG1: ≤35K: 34.4%; 35-50K: 22.9%; 57-75K: 11.4%; >75K: 31.4%; unknown: 0%G2: ≤35K: 25.8%; 35-50K: 16.1%; 50-75K: 38.7%; >75K: 16.1%; unknown: 3.23%**Depression score mean (SD):**Overall N: NRG1: 0.47 (0.46)G2: 0.42 (0.54)**BL adherence:**Overall N: NRG1: 54%G2: 46% | Column Q: NIH, Pharma company (Alcon), grant from the Paul & Evanina Bell Mackall Foundation Trust, and the Wilmer Institute Research Program. |
| Pearce et al., 200839Cardiovascular Risk Education and Social Support (CaRESS) Trial | Overall N: Mean (SD) = 62.1 (10.79)G1: Mean (SD) = 60.3 (9.44)G2: Mean (SD) = 62.0 (11.51)G3: Mean (SD) = 63.1 (10.98) | Overall N: 55.3%G1: 48.0%G2: 65.5% | **White**Overall N: 86.9%G1: 88.0%G2: 82.8%**African-American**Overall N: 13.1% G1: 12.0%G2: 17.2% | Yes | **Health insurance (%)**Group/private: Overall N: 60.9%G1: 53.1%G2: 51.9%G3: 70.3% Medicaid/Medicare: Overall N: 32.8%G1: 32.7%G2: 42.3%G3: 27.5%Other: Overall N: 1.0%G1: 0.0%G2: 3.7%G3: 0.0%None: Overall N: 5.2%G1: 14.3%G2: 1.9%G3: 2.2%**Employment (%)**Employed: Overall N: 37.5%G1: 47.9%G2: 35.2%G3: 33.3%Retired: Overall N: 47.9%G1: 37.5%G2: 46.3%G3: 54.4%  | **Other Theoretical model** = Self-efficacy theories also incorporated |
| Pearce et al., 200839Cardiovascular Risk Education and Social Support (CaRESS) Trial(continued) |  |  |  |  | Unemployed/ disabled: Overall N: 14.6%G1: 14.6%G2: 18.5%G3: 12.3%**Education (%)**< Some high school: Overall N: 16.6%G1: 20.0%G2: 13.8%G3: 16.5%High school/GED: Overall N: 41.2%G1: 44.0%G2: 39.7%G3: 40.7% 2-year degree/some college: Overall N: 22.6%G1: 16.0%G2: 25.9%G3: 24.2%> 4-year college graduate: Overall N: 19.6%G1: 20.0%G2: 20.7%G3: 18.7% |  |
| Powell et al., 199540NA | Overall N: NRG1: Mean (range) = 54 (20-94)G2: 55 (20-97) | Overall N: NRG1: 65%G2: 68% | NR | No | NA | **Funding source - Multiple** = Pharma (Merck & Co.) and corporate (Ciba-Geigy)**Theoretical model - Other** = NS |
| Powers et al., 201168 | Overall N: 67 (8)G1: 68 (9)G2: 65 (8) | Overall N: 2%G1: 2%G2: 2% | **White**Overall N: 51%G1: 50%G2: 51%**Black**Overall N: 45%G1: 46%G2: 44% | Yes | **Self-reported medication nonadherence**, %:Overall N: 49%G1: 50%G2: 49%**Self-reported medication adherence** (Morisky scale), %:Overall N: NRG1: 50%G2: 51%**Diabetes**, %:Overall N:55%G1: 48%G2: 62%**CHD**, %:Overall N:44%G1: 48%G2: 40%**Atrial fibrillation**, %:Overall N:9%G1: 9%G2: 9%**Left ventricular hypertrophy**, %:Overall N:27%G1: 27%G2: 27% | NA |
| Pyne et al., 201141HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Overall N: 249G1: 49.8(8.7)G2: 49.8(10.5) | Overall N: 7G1: N: 3G2: N: 4 | **African American**Overall N: 155G1: 63.4%G2: 61.6% | Yes | **Income greater than $20K:** G1: 60 (50.8%)G2: 52 (42.6%)**Physical health comorbidity score, mean (SD):** G1: 3.2 (2.3)G2: 3.8 (2.3)p=.046 | col X: theory of Other  |
| Rich et al., 199642NA | Overall N: 80 (median)G1: 80.5 (6.7)G2: 78.4 (6.1)p: 0.029 | Overall N: 67%G1: 74%G2: 59%p: 0.079  | **Caucasian**Overall N: 35%G1: 40%G2: 29% | Yes | **Education > 8th grade, %:**Overall: NRG1: 60%G2: 51%**Hypertension, %:**Overall: NRG1: 81%G2: 83%**Diabetes, %:**Overall: NRG1: 25%G2: 32%**Prior heart failure, %:**G1: 68%G2: 82%p 0.067 | **Other Theoretical model:** Not specified**Heart rate, mean**:\*G1: 92 (+/- 20)G2: 83 (+/- 19)p: 0.004\***Hemoglobin (g/L), mean**:G1: 125 (+/- 18)G2: 120 (+/- 19)p: 0.087**Creatinine (mmol/L), Mean**:G1: 137 +/- 66G2: 158 +/- 83p: 0.083**Serum Cholesterol (mmol/L), mean:**G1: 5.3 +/- 1.3G2: 4.8 +/- 1.4p: 0.052 |
| Rickles et al., 200543NA | Overall N: 63G1: 37.8 ± 10.7G2: 37.5 ± 13.4 | Overall N: G1: 25 (80.6%)G2: 28 (87.5%) | **White**Overall N: G1: 27 (87.1)G2: 31 (96.9)**Other:**Overall N:G1: 4 (12.9)G3:1 (3.1) | Yes | **Current number of medications other than antidepressants** Overall N: G1: 0.87 ± 1.41G2: 0.78 ± 1.16**No past history of psychiatric medication use, No. (%)**G1:18 (58.1) G2:27 (84.4) **Past use of psychiatric medications, No. (%)**G1:13 (41.9)G2: 5 (15.6)P<.05 | **Other Teoretical Model** = health collaboration model |
| Ross et al., 200444NR | Overall N: NRG1: 57 (NR)G2: 55 (NR) | Overall N: NRG1: 20 G2: 26 | **White, non-Hispanic**Overall N: NRG1: 92G2: 88 | Yes | **College graduate, %**Overall N: NRG1: 53G2: 44p <0.001 comparing participants to decliners (26% in decliners)**Household income<$45,000/year, %**Overall N: NRG1: 56G2: 50p <0.001 comparing participants to decliners (76% in decliners)**Safety net insurance program, %**Overall N: NRG1: 19G2: 19**Morisky BL score** Overall: 3.4G1: NRG2: NR**GAS BL score:**Overall: 82G1: NRG2: NR | **Other Theoretical model:** NS |
| Rudd et al., 200445NA | Overall N: NRG1: 59 (10)G2: 60 (9) | Overall N: NRG1: 50G2: 56 | **White**Overall N: NR G1: 76G2: 72**African American**Overall N: NR G1: 11G2: 8**Asian American**Overall N: NRG1: 4G2: 4**Hispanic**Overall N: NRG1: 1G2: 8**Other ethnicity**Overall N: NR G1: 8G2: 8 | Yes | **Some high school, %**Overall N: NRG1: 5G2: 5**High school graduate, %**Overall N: NRG1: 17G2: 19**Some college, %**Overall N: NRG1: 24G2: 23**College degree, %**Overall N: NRG1: 27G2: 31**Postdoctoral degree, %**Overall N: NRG1: 27G2: 22**Dyslipidemia, %** (p<0.05)Overall N: NRG1: 16G2: 30 | **Other Funding**: CorSolution’s, Inc.  |
| Rudd et al., 200946NA | Overall N: 127G1: Mean 57.6 (13.8)G2: Mean 59.5 (13.9) p=0.43%≥65 years oldG1: 25%G2: 43%p: 0.03 | Overall N: 127G1: 81G2: 78 | **Caucasian**Overall N: 127G1: 91G2: 94 | Yes | **Annual income <$30K**Overall N: 127G1: 20%G2: 39%p=0.02 | Other Study Design: RCT with stratified randomization based on education level.  |
| Schaffer et al., 200447NA | Overall N: 44mean age 37G1: NRG2: NRG3: NRG4: NRNo statistical differences across groups | Overall N: 29/44 (65.9%) G1: NRG2: NRG3: NRG4: NRNo statistical difference across groups | 17% AA, 72% white, 1% Hispanic, Asian, or Pacific Islander; not reported by study arm; no statistical differences across groups | No | No baseline characteristics reported by study arm; however, across all study arms authors report that there were no statistical differences in years since asthma diagnosis, education, self-reported adherence, pharmacy-reported adherence, or baseline FEV1.  |   |
| Schectman et al., 199448NA | NiacinOverall N: NRG1: 59 (1)G2: 62 (1)BASOverall N: NRG1: 61 (2)G2: 59 (2) | NiacinOverall N: NRG1: NRG2: NRBASOverall N: NRG1: NRG2: NR | **Caucasian** NiacinOverall N: NRG1: 86G2: 90**BAS**Overall N: NRG1: 86G2: 82 | Yes | **CHD, Diabetes, HTN, %**NiacinOverall N: NRG1: 39, 2, 56G2: 42, 4, 63**BAS**Overall N: NRG1: 35, 24, 62G2: 37, 13, 52 | **Multiple funding sources:** Gov’t, Pharma (Squibb-Bristol)**Other Theoretical model:** NS |
| Schneider et al., 200849NA | Overall N: 85G1: 71.6 (5.9)G2: 72.3 (5.2)  | Overall N: 85G1: 24.7G2: 25.9 | Overall N: 85G1: NRG2: NR | yes | **Renal impairment (SCr>1.2mg/dl)**Overall N: 85G1: 6.5G2: 7.9 |   |
| Schnipper et al., 200650NA | Overall N: 176G1: 60.7 (17.2)G2: 57.7 (15.9) | Overall N: 176G1: 67G2: 65 | Overall N: G1: NRG2: NR | No | NA | **Other Funding Source**: Pharma, university, Gov’t |
| Simon et al., 200651NA | Overall N: G1: 41±15G2: 45±13 | Overall N: G1: 71 (69%)G2: 63 (61%) | **White**Overall N: G1: 92 (89%)G2: 93 (89%) | Yes | **Severity: SCL depression scale**Overall N: G1: 1.61±.68 G2: 1.57±.71**Patient Health Questionnaire score** (0 to 27 range; higher scores indicate more severe depression)G1: 16.0±6.2 G2: 15.8±6.195% CI, p: .84 | **Other Funding Source:** funding from gov't and pharma**Other Theoretical Model**: NS |
| Sledge et al., 200652NA | Overall N: 96G1: 53 (range 24-84)G2: 49 (range 23-80) | Overall N: 96G1: 26G2: 41 | Overall N: 96**Caucasian**G1: 32G2: 31**African American**G1: 49G2: 51**Hispanic**G1: 13G2: 12 | Yes | **Medicare/Medicaid**Overall N: 96G1: 95%G2: 92%**Gross income <$20K**G1: 89%G2: 86%**Congestive heart failure**G1: 17%G2: 12%**Coronary artery disease**G1: 17%G2: 18%**COPD**G1: 23%G2: 16%**Diabetes mellitus**G1: 28%G2: 24%**ESRD/CRI**G1: 4%G2: 6%**Chronic pain**G1: 11%G2: 6%**Asthma**G1: 19%G2: 20% | **Other Funding Source:** Aetna health insurance company grant and Esther S. Gross Professorship**Other Conditions:** multiple conditions, NS |
| Smith et al., 200853NR | Overall: NRG1: 64.69 (14.19)G2: 65.04 (13.38) | Overall: NRG1: 31.3G2: 34.0 | NR | Yes | **Medicare, %**Overall: NRG1: 46.4G2: 47.1**Medicaid, %**Overall: NRG1: 1.6G2: 1.6**Adherence, Proportion of days covered in month before intervention, %**G1: 87G2: 86 | No theoretical model specified |
| Solomon et al., 199854NAGourley et al., 199855NA | Overall N (HTN); NRG1: 66.3 (10.0 SD)G2: 67.3 (11.0 SD)Overall (COPD): NRG1: 69.3 (5.9 SD)G2: 69.3 (9.2 SD) | Overall N (HTN): NRG1: 1.6%G2: 7.1%Overall (COPD): NRG1: 0G2: 0 | **Overall N (HTN)**: NRG1: Caucasian 61.9%Black 34.9%Asian 0Hispanic 0Missing 3.2%G2: Caucasian 65.7%Black 22.9%Asian 1.4%Hispanic 0Missing 10.0%**Overall N (COPD)**: NRG1: Caucasian 90.7%Black 2.3%Asian 0Hispanic 7.0%Missing 0G2: Caucasian 83.6%Black 7.3%Asian 0Hispanic 9.1%Missing 0 | Yes | **Income**: **(HTN):** Overall: NRG1: $18,254 (12,259 SD)G2: $19,548 (16860 SD)**Income: (COPD):**Overall: NRG1: $20,908 (17,977 SD)G2: $21,022 (13,029 SD) | **Notes:** Medication adherence improved in hypertension arm; medication adherence did not improve in COPD arm (measures not reported in COPD arm) |
| Stacy et al., 200956NA | <50 yrs old (%)Overall N: 28.0G1: 25.3G2: 30.550-64 yrs old (%)Overall N: 62.4G1: 64.4G2: 60.265 yrs or older (%)Overall N: 9.7G1: 9.0G2: 10.3 | Overall N: 62.4G1: 62.1G2: 62.7 | Overall N: NRG1: NRG2: NR | Yes | **Mean of 3+ chronic medications dispensed =<90 days prior to index statin (%)**Overall N: 57.8G1: 53.4G2: 62.3**Statin adherence: % started statin, never missed dose**Overall N: 72.9G1: 71.5G2: 74.1**Statin adherence: % started statin, missed 1+ dose**Overall N: 21.9G1: 22.1G2: 21.7**Statin adherence: % not yet started statin**Overall N: 5.2G1: 6.3G2: 4.2 | Funding Source: NR |
| Taylor et al., 200357NA | Overall N: 69G1: 64.4 (13.7)G2: 66.7 (12.3) | Overall N: 69G1: 63.6G2: 72.2 | **White**Overall N: 69% G1: 60.6G2: 61.1 | Yes | **Mean % (SD) adherent at BL (compliance scores ≥80%):**Overall N: 69G1: 84.9 (6.7)G2: 88.9 (5.8) | **Other Conditions:** multiple conditions**Other Theoretical Model:** Principles of Pharmaceutical Care |
| Vivian et al., 200258NA | Overall N: NRG1: 64 (10.9)G2: 65.5 (7.8) | Overall N: NRG1: 0G2: 0 | **African American**Overall N: 77G1: 84.6G2: 70.4**Caucasian**Overall N: 77G1: 11.5G2: 25.9 | Yes | **Diabetes, %**Overall N: NRG1: 42G2: 59 | **Other Theoretical model:** not specified |
| Waalen et al., 200959NA | Overall N: 237G1: 71.3 (7.3) G2: 70.5 (12.6) | Overall N: 237G1: 100%G2: 100% | **White**Overall N: 237G1: 91.2G2: 98.2**Hispanic**Overall N: 237G1: 2.4G2: 0.9**Asian**Overall N: 237G1: 5.6 G2: 0.9 **Black**G1: 0.8G2: 0 | No  | NA  | NA. |
| Wakefield et al., 201160NA | Overall N: 68 (10)G1: 67.8 (10)G2: 68.4 (9.5)G3: 69.9 (9.9) | Overall N: 2%G1: 1%G2: 1%G3: 4% | **American Indian/Alaska Native**Overall N: NRG1: 0%G2: <1%G3: 2%**Black/African American**Overall N: NRG1: 3%G2: 2%G3:<1%**Hispanic**Overall N:NR G1: 0%G2: <1%G3: <1%**White**Overall N: 96%G1: 97%G2: 96%G3 95% | No | NA | NA |
| Weinberger et al., 200261NA | COPD:mean (SD)Overall N: 453G1: 62.2 (11.0)G2: 62.9 (10.3)G3:62.2 (11.9)Asthma:Overall N: 660G1: 44.7 (14.2)G2: 46.6 (15.1)G3:44.6 (15.5) | COPD: number (%)Overall N: 453G1:118 (63.8)G2: 86 (66.2) G3:93 (67.4)Asthma:Overall N: 660G1: 210 (80.2)G2: 190 (81.6) G3:139 (84.2) | **White**, %COPD: number (%)Overall N: 453G1:149 (80.5)G2: 116 (89.2)G3:127 (92.0) Asthma:Overall N: 660G1: 197 (75.2)G2: 189 (81.1)G3:145 (87.9) | Yes | **Medication compliance, No (%) not compliant**COPDOverall N: 453G1: 64 (34.8) G2: 46 (35.4) G3: 54 (39.0) Asthma:Overall N: 660G1: 91 (34.7) G2: 77 (33.1) G3: 61 (37.2) | **Other Randomization**: randomization was stratified within cluster of 3 proximal drugstores**Other Theoretical Model**: not reported |
| Weinberger et al., 200261NA(continued) |  |  | within both conditions, race differed by group (p<0.05) |  | **Med compliance - 4 item measure, mean SD**COPDOverall N: 453G1: 1.3 (1.2)G2: 1.1 (1.0) G3: 1.0 (1.1) AsthmaOverall N: 660G1: 1.4 (1.1) G2: 1.2 (1.1) G3: 1.4 (1.2)**Peak expiratory flow rates (PEFR), mean SD, % predicted**COPD:Overall N: 453G1: 52.1 (21.1) G2:46.4 (19.8)G3:48.1 (18.4) p<.05Asthma:Overall N: 660G1:70.0 (18.0)G2:69.5 (18.5) G3:70.8 (19.2)p>=.05 | **Note**: baseline characteristics presented stratified by disease (COPD vs.asthma) |
| Weymiller et al., 200762Statin Choice Randomized TrialJones et al., 200963Statin Choice Randomized Trial | Overall N: Mean (SD) = NR G1: Mean (SD) = 64 (12)G2: Mean (SD) = 66 (8)Overall N: Mean (SD) = NRG1: Mean (SD) = 65.4 (11.1)G2: Mean (SD) = 63.4 (12.7)G3: Mean (SD) = 67.4 (8.0)G4: Mean (SD) = 65.8 (8.1) | Overall N: NRG1: 31%G2: 57%Overall N: NRG1: 26.9%G2: 34.6%G3: 56.5%G4: 56.5% | NR | Yes | **Diagnosis of CAD**G1: N (%) = 26 (50%)G2: N (%) = 20 (43%)**United Kingdom Prospective Diabetes Study (UKPDS) estimated 10-year** **Cardiovascular risk <15%**G1: N (%) = 6 (12%)G2: N (%) = 15 (33%)**15-30%**G1: N (%) = 16 (31%)G2: N (%) = 7 (15%)**>30%**G1: N (%) = 30 (58%)G2: N (%) = 24 (52%)**Diagnosis of CAD**G1: N (%) = 15 (57.7%) | **Other Randomization** = Providers were randomized to treatment or control, and patients were randomized to receive the intervention or control materials either from their clinician during the visit or from a researcher before the visit**Funding source - Multiple** = Foundation/non-profit and Mayo Clinic-affiliated patient education center **Other****Theoretical model** - Other = NS**BL characteristics - Other** =High school education completedOverall N: NRG1: N (%) = 51 (98%)G2: N (%) = 39 (87%)High school educationOverall N: NRG1: N (%) = 25 (96.2%)G2: N (%) = 26 (100.0%) |
| Weymiller et al., 200762Statin Choice Randomized TrialJones et al., 200963Statin Choice Randomized Trial(continued) |  |  |  |  | **UKPDS estimated 10-year cardiovascular risk<15%**G1: N (%) = 4 (15.4%)G2: N (%) = 2 (7.7%)G3: N (%) = 8 (34.8%)G4: N (%) = 7 (30.4%)**15-30%**G1: N (%) = 7 (26.9%)G2: N (%) = 9 (34.6%)G3: N (%) = 5 (21.7%)G4: N (%) = 2 (8.7%)**>30%**G1: N (%) = 15 (57.7%)G2: N (%) = 15 (57.7%)G3: N (%) = 10 (43.5%)G4: N (%) = 14 (60.9%) | G3: N (%) = 22 (95.7%)G4: N (%) = 17 (77.3%) |
| Williams et al., 201064NA | Overall N: 2698G1: 26.8 +/- 17.4G2: 28.8 +/- 17.4 | Overall N: 1490G1: 737 (55.2%) G2: 753 (55.3%) | **African American**Overall N: 1039G1: 511 (38.3) G2: 528 (38.7)**White**Overall N: 1475G1: 726 (54.4)G2: 749 (55.0)**Other**Overall N: 184G1: 98 (7.3) G2: 86 (6.3) | No | NA | **Other Theoretical model**: none**Other randomization**: clustered randomization was stratified by type of clinical practice: pediatrics vs. family medicine and internal medicine**Notes:** Usual care group was given extensive educational materials in a variety of formats. G1 providers given opportunity to access adherence data in addition.  |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT); note that there is online supplemental material for methods and timeline | Overall N:612G1: 45.7 +/- 13.3G2: 46.9 +/- 12.1G3: 45.1 +/- 12.4 | Overall N: G1: 115 (56.4)G2: 114 (55.9)G3: 117 (57.4) | **Caucasian** G1: 128 (62.8)G2: 124 (60.8) G3: 127 (62.3) AAG1: 32 (15.7)G2: 34 (16.7) G3: 30 (14.7)**Asian**G1: 20 (9.8)G2: 18 (8.8)G3: 22 (10.8) HispanicG1: 9 (4.4)G2: 9 (4.4)G3: 8 (3.9)**Pacific Islander**G1: 15 (7.4)G2: 16 (7.8)G3: 17 (8.3)**American Indian**G1: 0 (0.0)G2: 3 (1.5)G3: 0 (0.0) | Yes | **Severity Level of Asthma control:**Very poorly controlledG1: 79 (38.7)G2: 82 (40.2)G3: 85 (42.1)Poorly controlled:G1: 96 (47.1)G2: 87 (42.7)G3: 83 (41.1)Moderately well controlled:G1: 17 (8.3)G2: 24 (11.8)G3: 29 (14.4)Well controlled:G1: 12 (5.9)G2: 11 (5.4)G3: 5 (2.5)**Hospitalized for asthma in past 2 years**G1:71 (34.8)G2: 69 (33.8)G3: 76 (37.3)**Income >/=40K/yr**G1: 133 (66.8)G2: 139 (70.9)G3: 134 (69.1)  | NA |
| Wolever et al., 201066NA | Overall N: 53 (7.93)G1: 53.1 (8.29)G2: 52.8 (7.64) | Overall N: 77%G1: 73%G2: 81% | **White**Overall N: 39% G1: 33%G2: 46%**Black**Overall N: 57%G1: 63%G2: 50%**Other**Overall N: 4%G1: 3%G2: 4% | Yes | **Household income < $50,000**Overall N: 55%G1: 57%G2: 54%**Household income > $50,000**Overall N: 45%G1: 43%G2: 46% | **Theoretical model - other** = Integrative health coaching |
| Zhang et al., 201067NA | **Hyperlipidemia** (N = 9185): G1 (Age %): 65-74 years, 40.2%; 75-84 years, 53.6%; >85 years, 6.2%G2 (Age %): 65-74 years, 52.4%; 75-84 years, 41.1%; >85 years, 6.5% G3 (Age %): 65-74 years, 54.7%; 75-84 years, 40.3%; >85 years, 5%G4 (Age %): 65-74 years, 62%; 75-84 years, 34.3%; >85 years, 3.7%  | **Hyperlipidemia**: G1: 68.4G2: 65.4G3: 61.5G4: 50.9**Diabetes**G1: 60.3G2: 58.2G3: 56.7G4: 47.6**Hypertension**G1: 69.3G2: 66.4G3: 64.7G4: 53.8G4 differs from G1, G2, and G3 at p < 0.05 | **Hyperlipidemia:****Proportion of white beneficiaries** G1: 92.3G2: 96G3: 92G4: 92.2G2 vs. G4, p < 0.05**Diabetes:****Proportion of white beneficiaries** G1: 92.8G2: 96.2G3: 92.1G4: 91.5G2 vs. G4, p < 0.05**Hypertension:****Proportion of white beneficiaries** G1: 91.6G2: 96.0G3: 91.6G4: 91.7G2 vs. G4, p < 0.05 | Yes | **Hyperlipidemia**:Median Income ($), mean (SE) Among 65-74 year oldsG1: 26,440 (261)G2: 25,865 (153)G3: 28,782 (92)G4: 28,948 (118)Among >75 year oldsG1: 19,798 (200)G2: 19,124 (123)G3: 20,796 (63)G4: 20,992 (79)Proportion living in Urban areasG1: 72.1G2: 60.5G3: 80G4: 80.2G1 and G2 differ from G4 at p < 0.05 | **Other level of randomization** = NA**Multiple funders** = government, nonprofit, and academic**Other theoretical model** = NS |
| Zhang et al., 201067NA(continued) | **Diabetes** (N = 4018)G1 (Age %): 65-74 years, 41.3%; 75-84 years, 49.8%; >85 years, 8.9% G2 (Age %): 65-74 years, 50%; 75-84 years, 42.8%; >85 years, 7.2% G3 (Age %): 65-74 years, 54%; 75-84 years, 39.7%; >85 years, 6.3%G4 (Age %): 65-74 years, 60.7%; 75-84 years, 34.9%; >85 years, 4.5% **Hypertension** (N = 14,735)G1 (Age %): 65-74 years, 37.3%; 75-84 years, 48.6%; >85 years, 14.1%G2 (Age %): 65-74 years, 44.7%; 75-84 years, 44.6%; >85 years, 10.8%G3 (Age %): 65-74 years, 48.1%; 75-84 years, 42.5%; >85 years, 9.4% |  |  |  | **Diabetes**Median Income ($). Mean (SE) Among 65-74 year oldsG1: 26,740 (361)G2: 25,713 (207)G3: 27,854 (130)G4: 28,611 (178)Among >75 year oldsG1: 19,968 (260)G2: 19,024 (167)G3: 20,290 (92)G4: 20,642 (113)Proportion living in Urban areasG1: 74.1G2: 58.5G3: 77.5G4: 77.6G2 vs. G4, p < .05**Hypertension** Median Income ($), mean (SE) Among 65-74 year oldsG1: 26,940 (182)G2: 25,784 (107)G3: 28,427 (71)G4: 28,688 (100)Among >75 year oldsG1: 19,868 (128)G2: 19,168 (89)G3: 20,563 (47)G4: 20,875 (67) |  |
| Zhang et al., 201067NA(continued) | G4 (Age %): 65-74 years, 55.9%; 75-84 years, 37.9%; >85 years, 6.2%G4 differs from G1, G2, and G3 at p < 0.05 |  |  |  | Proportion living in Urban areasG1: 75.4G2: 57.9G3: 79.7G4: 80.3G2 vs. G4, p < 0.05 |  |